Amneal Pharmaceuticals, Inc.
AMRX
Κατάταξη σε μετοχές
#2968
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Τιμή μετοχής
$19.39
Τελευταίος συγχρονισμός: 2026-10-19
Κεφαλαιοποίηση
$6.19B
Αλλαγή (1 ημέρα)
1.09%
Αλλαγή (1 έτος)
89.36%
Χώρα
US
Εμπόριο Amneal Pharmaceuticals, Inc. (AMRX)
Κατηγορία
Healthcare
Κέρδη για την Amneal Pharmaceuticals, Inc. (AMRX)
Κέρδη τον Jun 2026 TTM: $201.18M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Amneal Pharmaceuticals, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $201.18M. Το 2023, η εταιρεία παρουσίασε κέρδη $-40.27M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $-248.13M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Amneal Pharmaceuticals, Inc. από 2014 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $201.18M | -465.69% |
| 2024 | $-55.01M | 36.61% |
| 2023 | $-40.27M | -83.77% |
| 2022 | $-248.13M | -891.07% |
| 2021 | $31.37M | -187.66% |
| 2020 | $-35.78M | -83.75% |
| 2019 | $-220.24M | 8.64% |
| 2018 | $-202.72M | -218.33% |
| 2017 | $171.32M | -20.25% |
| 2016 | $214.82M | 22.35% |
| 2015 | $175.58M | -2.09% |
| 2014 | $179.33M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 777.11% |
IN
|
